NCT00821483已完成3 期
Phase 3 Study to Assess the Efficacy and Safety of Frovatriptan
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 298
- 主要终点
- A comparison between Frovatriptan and placebo for the proportion of patients who have complete(grade 0) or almost complete(grade 1) relief of headache at 2 hours after taking Frovatriptan
研究概览
简要总结
The purpose of this study is:
- To compare the efficacy of a single dose of Frovatriptan 2.5 mg with that of placebo in acute treatment of up to one migraine attract
- To assess recurrence rate between two group
- To assess the safety and tolerability
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults aged 18 to 65 years
- •The patients must have a history of migraine according to the criteria of the Headache Classification Committee of the International Headache Society(IHS), over the previous 1 year. The patient must have experienced one to eight moderate or severe migraine attacks(with or without aura) each month over at least the previous two months
- •Onset of migraine disease must have occurred before the patients was 50 years of age
- •Able and willing to sign informed consent, and able and willing to comply with study procedures, including the completion of diary cards.
排除标准
- •Pregnant or lactating females, or women intend to become pregnant or breast feed during the study period, or women of childbearing potential not using adequate contraception. Females of reproductive potential must have a negative pregnancy test at screening
- •Clinically significant renal dysfunction(creatinine≥2.0mg/dl) or hepatic dysfunction(ALT,AST≥2 ULN)
- •Patients with clinically significant abnormal ECGs or with resting diastolic blood pressure above 95mmHg
- •Patients with clinically significant cardiovascular or cerebrovascular disease
- •Patients with a history of clinically relevant allergy, including allergy to triptan
- •Previous treatment with Frovatriptan at any time or treatment with an investigational drug within 30 days before screening visit
- •Patients with a diagnosis of vertebrobasilar or hemiplegic(prolonged atypical aura) migraine(IHS criteria)
- •Potentially unco-operative patients, those unable to provide informed consent, and those unable to complete the diary
- •patients who habitually abuse headache medication including ergotamine-containing compounds, and patients with a history of alcohol and/or medicine abuse, in the Investigator's opinion
- •Patients who are not able to tell that they are having a migraine headache
- •Patients who have 15 or more headache days per month, on average, or those taking symptomatic medication for headaches on more than two days per week, on average
- •Treatment with a monoamine-oxidase inhibitor(MAOI) within two weeks of the screening visit
- •Patients who are taking prophylactic migraine medication, unless dose has been stabilized for 30 days and it expected to continue for the duration of the study
研究组 & 干预措施
2 Frovatriptan
Active Comparator
干预措施: Frovatriptan (Drug)
1: placebo
Placebo Comparator
干预措施: Frovatriptan (Drug)
结局指标
主要结局
A comparison between Frovatriptan and placebo for the proportion of patients who have complete(grade 0) or almost complete(grade 1) relief of headache at 2 hours after taking Frovatriptan
时间窗: at 2 hours
次要结局
未报告次要终点
研究者
相似试验
已完成
3 期
A Randomized Trial of Frovatriptan for the Intermittent Prevention of Menstrual MigraineMenstrually Associated MigraineNCT00644033Endo Pharmaceuticals579
已完成
3 期
Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced AdultsHIVAcquired Immunodeficiency SyndromeHIV InfectionsNCT01967940Gilead Sciences55
进行中（未招募）
3 期
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal InsulinDiabetesNCT06767748Gan & Lee Pharmaceuticals.620
进行中（未招募）
3 期
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM)DiabetesNCT06767735Gan & Lee Pharmaceuticals.580
进行中（未招募）
3 期
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Type 2 Diabetes Mellitus Subjects (T2DM) Treated With Basal + Prandial InsulinDiabetesNCT06767761Gan & Lee Pharmaceuticals.580